Podcasts about GLP

This episode is brought to you by Joi & Blokes, Troscriptions, and Caldera Lab. In this episode of Ever Forward Radio, registered dietitian Ashley Koff, RD breaks down the truth behind GLP-1 medications like Ozempic and Wegovy, reframing them not as magic weight-loss shots but as hormone replacement therapies that reveal how dysfunctional most people's "weight-health hormones" have become. Ashley shares how digestion, nutrient status, genetics, and modern environmental pressures diminish the body's natural ability to regulate appetite, cravings, metabolism, and fat distribution — and why GLP-1 drugs can offer clarity but not a cure unless the underlying issues are addressed. She dives into muscle preservation, the limitations of BMI, the importance of fat-mass vs. scale weight, the root-cause approach to sustainable weight health, and what the future of GLP-1s means for generational wellness. This is a powerful conversation that blends science, personal insight, and actionable strategies to improve metabolic health — with or without medication. Follow Ashley @ashleykoffapproved Follow Chase @chase_chewning ----- 00:00 – GLP-1 hype: weight loss, risks, and whole-body benefits 02:00 – What GLP-1 drugs actually do in the body 02:20 – Understanding "weight-health hormones" 03:00 – Why society is functioning with suboptimal hormones 12:00 – Why total weight doesn't matter — muscle, fat, and bone do 14:00 – BMI is broken and misleading 15:00 – Weight regain, muscle loss, and metabolism 17:00 – Genetics, survival traits, and appetite regulation 23:00 – Root-cause approach: digestion, nutrient status, vagus nerve work 26:00 – How GLP-1s validate hormone dysfunction 28:00 – Side effects like nausea and constipation explained 30:00 – Why digestive repair is essential for long-term success 33:00 – How GLP-1s quiet obsessive thoughts, cravings, and food noise 36:00 – Supplements that support GLP-1 and weight-health hormone function 38:00 – Hop extract research and natural "GLP-1 activators" 42:00 – Limitations of natural alternatives vs. true hormone replacement 1:12:00 – Glucose spikes, CGMs, and metabolic flexibility 1:27:00 – The future of GLP-1s and redefining "obesity" 1:28:00 – Generational weight health and epigenetics 1:29:00 – Final thoughts and Ashley's Ever Forward message ----- Episode resources: Get 50% off any diagnostic labs with code CHASE at https://www.JoiAndBlokes.com/chase  Try CALM and save with checkout code EVERFORWARD at https://www.Troscriptions.com/everforward  Get 20% off the best men's skincare with code EVERFORWARD at https://www.CalderaLab.com  Watch and subscribe on YouTube Get Ashley's book on Amazon

Lately, your feed might be full of “wellness” influencers suddenly crediting their transformation to GLP-1 meds. But here's the thing: when health creators start shrinking themselves for clicks, it sends a dangerous message … that thinner automatically means healthier. In this episode, we're talking about the real cost of chasing a smaller body: disrupted hormones, slower metabolism, higher injury risk, and the constant anxiety that comes with fighting your genetics. As a dietitian and lifelong runner, I'm breaking down why sustainable health has nothing to do with suppressing your biology and everything to do with fueling it.   Interested in trying Soul CBD? Use my code serena to get 30% off! Don't forget to follow me on Instagram @runnergirldietitian

The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]http://www.transcendcompany.com/nylenaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:00:00:00 – Intro00:02:28 – Remote vs. In-Person Peaking00:03:50 – Data Driven Coaching00:06:13 – First Cycle Philosophy00:09:31 – Post-Show Buffer Protocol00:11:02 – The Estrogen Myth00:14:14 – The Calcium Score Imperative00:15:59 – The Vitamin D3 Danger00:17:49 – Death by Potassium00:20:23 – Halo vs. Superdrol00:27:37 – Thyroid Tapering00:30:59 – Western Medicine vs. Bodybuilding00:33:16 – The Rebound Phase00:37:42 – Female Androgen Health Effects00:44:31 – Metformin vs. Berberine00:48:18 – Myostatin & The Future of PEDs00:52:23 – Training is what matters most00:58:00 – Fixing Back Training01:05:26 – From Dietitian to Super Coach01:14:32 – Insulin Sensitivity & Gut Health01:23:03 – Peak Week Glucose & GI Health Management01:31:01 – The Dyazide Strategy01:41:02 – The GLP-1 Trap01:54:31 – Classic Physique Weight Cuts01:56:14 – Stanimal Case Study02:09:48 – Insulin & HGH Synergy02:15:42 – Why Modern Bodybuilding is Soft02:21:35 – Designing the Offseason Cycle02:37:05 – Waist Control Secrets02:40:33 – Nick Walker & Coaching02:43:27 – Female PED Safety02:52:36 – Fertility & Sperm Banking02:55:40 – The Final Message

I've learned so much throughout 2025 as a coach and business owner and I wanted to have a reflective and educational episode for you today on what stood out to me the most in this industry specifically. These top 10 trends or fads I noticed throughout the year drove me absolutely crazy as a functional health coach and I don't want you to fall victim to these.   Time Stamps:   (0:45) More Everything Than Ever Before (4:40) #1: Hormone Pellets (12:20) #2: GLP 1's Promoted Through Social Media (16:03) #3: Med Spa Hormonal Clinics (17:35) #4: Peptides (19:47) #5: Fear Based Food Rules (21:56) #6: Aggressive Intermittent Fasting (23:55) #7: Self-Diagnosing From Social Media (25:32) #8: Weight Loss Drugs With No Attention to Muscle (27:35) #9: Testing Obsession With No Interpretation (32:35) #10: The 1200 Calorie Woman ----------  Apply for SF Coaching Method  https://sarahfechter.ac-page.com/sfhq-cc Complimentary Health Content  https://sarahfechter.ac-page.com/Health_Wellness_Community ----------  Follow Me On Instagram - https://www.instagram.com/sarahfechter.ifbbpro/   Check Out My Website - https://www.sarahfechter.com ----------  This Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, other professional health care services, or any professional practice of any kind. Any reliance on the information provided in this Podcast is done at your own risk and Sarah Fechter Fitness LLC expressly disclaims any and all liability or responsibility for any direct, indirect, incidental, special, consequential or other damages arising out of any individual use of, reference to, reliance on, or inability to use, this Podcast or the information presented in this Podcast. All contents and design for this Podcast are owned by Sarah Fechter Fitness LLC. Always consult your professional team before beginning any exercise or nutrition program.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener questions about BMI cutoffs, weight cycling, metabolic adaptation, trauma, GLP-1 differences, and why some people gain weight on ultra-low calories. Dr. Cooper explains what's really happening inside the metabolic system and why individualized treatment—not dieting—creates sustainable change.Key Questions AnsweredIf my BMI doesn't “qualify” for GLP-1s, is Naltrexone + Bupropion helpful—and what labs matter first?Does being overweight always indicate metabolic dysfunction, and why are U.S. rates so high?If diets damage metabolism, what do you do when you're already 80 pounds overweight?How long does it take for leptin and ghrelin to stabilize with mechanical eating?How can someone gain weight on 1,200 calories/day?After sleeve gastrectomy, how do you eat enough while on a GLP-1?Is set point theory real—and how does the melanocortin pathway influence it?If obesity runs in my family, will I need meds like Zepbound for life?How do trauma and stress alter long-term metabolic health?Can GLP-1s offset weight gain from steroids, mood meds, or hormones?Why might Ozempic work well while Mounjaro causes weight gain?Key Takeaways1. BMI rules don't reflect metabolic truth.A mid-20s BMI can still mask significant dysfunction, especially with weight cycling.2. Weight cycling is metabolically stressful.Repeated losses/regains increase visceral fat, insulin abnormalities, and cardiovascular risk.3. Obesity is a multi-hormonal disease.Most people need pharmacology plus sleep, fueling, and movement—not restrictive dieting.4. Metabolic adaptation is powerful.Under-fueling lowers thyroid output, suppresses fat-burning, and slows metabolism dramatically.5. After bariatric surgery or on GLP-1s, frequency matters.Frequent, nutrient-dense snacks protect muscle, metabolism, and energy.6. Set point changes with better signaling.GLP-1s and related therapies help the brain accurately detect weight and lower the defended level.7. Genetics often mean lifelong support.Family patterns of obesity usually indicate long-term need for metabolic medication.8. Trauma amplifies metabolic risk.Childhood trauma disrupts IGF-1, sleep, stress hormones, insulin, leptin, and ghrelin.9. Medications can cause weight gain—GLP-1s can help counteract it.Steroids, mood meds, hormonal agents, and more can be metabolically unfriendly.10. “Newer” isn't always better.Some people respond poorly to the GIP component in Mounjaro/Zepbound. Individual physiology rules.Dr. Cooper's Actionable TipsRequest deeper evaluation: DEXA, visceral fat, fasting insulin/glucose, leptin, reproductive hormones.Stop restrictive dieting permanently—mechanical eating protects metabolic stability.Work with a fueling-focused dietitian (often ED-trained).Review your medication list for drugs known to cause weight gain.Don't switch GLP-1s or chase higher doses if your current regimen works.Notable Quote“Obesity isn't a willpower problem. It's a metabolic disease, and when the underlying system is supported, the body finally has permission to change.” — Dr. Emily CooperLinks & ResourcesPodcast Home: Fat Science Podcast WebsiteSubmit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comDr. Emily Cooper on LinkedInMark Wright on LinkedInAndrea Taylor on InstagramFat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice.

✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

Send us a message with this link, we would love to hear from you. Standard message rates may apply.We share a quick life update, welcome our first guest Mike Rozanski, and clear up the Michelin Guide origin story before shifting to a focused guide on starting GLP-1 medications. Practical strategies cover injections, nausea, constipation, muscle protection, and adjusting other meds safely.• board certification in obesity medicine and motivation to destigmatise care• guest segment on Michelin guide history and Philly's recent stars• what GLP-1 meds are and how auto-injectors work• portion sizing to prevent nausea and early side effects• fiber with fluids to prevent constipation• protein targets and simple strength training to protect muscle• when to adjust blood pressure and diabetes medications• key takeaways and encouragement to start small and follow upIf you found this helpful, a review really does go a long way for a like on whatever app you're listening to us onSupport the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

In this week's Monday News Drop, Co-hosts Bo Brabo and Luke Carignan, along with ASHHRA Executive Director, Jeremy Sadlier, break down the biggest healthcare HR trends and policy changes shaping the road to 2026—what HR leaders need to watch, prepare for, and take action on now. From telehealth reimbursement cliffs to workplace violence standards and double-digit benefit increases, this episode arms you with a strategic playbook for the year ahead.

f you've ever reached for food even when your stomach isn't hungry, this episode is for you. Physical hunger can be solved with tools like intermittent fasting, GLP-1 medications, or Zero Hunger Water—but emotional hunger is a different beast. It's the stress, pain, trauma, and unresolved story that drives cravings long after your body is full.In this episode, Jorge reveals how emotional hunger forms, why it's stronger than physical hunger, and how dopamine plays a powerful role in cravings. He shares his own journey through loss, estrangement, midlife collapse, alcohol coping, recovery, and learning to rewrite the story—moving from victimhood to empowerment.You'll discover:• Why emotional hunger makes you eat even when you're not physically hungry• How childhood and midlife trauma silently fuel cravings• Why sugar, carbs, and alcohol feel like “relief” but backfire• The clean dopamine-boosting habits that actually work• How to replace emotional eating with “dopamine wins” that lift you up• A mindset shift inspired by Tony Robbins that changes everythingThe episode ends with the original AI-created song “Needed This” by Victor Sol, a metaphorical reminder that the hardest moments can become our biggest gifts.Listen to “Needed This” by Victor Sol:Apple Music: https://music.apple.com/us/album/needed-this/1857899581?i=1857899582Spotify: https://open.spotify.com/track/7K5kxVNkD2y6Y1hpnzGnji?si=aac8dc2580e04a77Instagram: https://www.instagram.com/iamvictorsolTry the AI song-writing tool Jorge used:https://www.jorgecruise.com/p/sunoJoin the FREE Live Zoom Event on December 8 at 5:30pm PT:Turn Off Hunger: https://www.jorgecruise.com/p/turn-off-hungerhttps://us06web.zoom.us/j/83964851796?pwd=h6aVopb3X3cdy3b0j60nmwbADGarC7.1Share this episode with anyone who struggles with emotional eating. This one may help them finally understand what's really going on beneath the cravings.

What are GLP-1's? Is it a good option? What are the other options out there for me? Why can't I lose weight?

We're continuing Best of the Best, our series profiling some of Australia's top investors and the processes behind their performance.Today we're joined by Anshu Sharma, portfolio manager and co-founder of Loftus Peak, to unpack how a pure-play disruption investor thinks about Nvidia, AI, semiconductors, GLP-1 drugs and more.In this episode:How Loftus Peak finds long-term structural trends (and filters out short-term hype)Which trends are still early in their disruption lifecycleThe process edge: building a 3–5 year view, strict valuation discipline and knowing when to walk away———Want to get involved in the podcast? Record a voice note or send us a message And come and join the conversation in the Equity Mates Facebook Discussion Group———Want more Equity Mates? Across books, podcasts, video and email, however you want to learn about investing – we've got you covered.Keep up with the news moving markets with our daily newsletter and podcast (Apple | Spotify)We're particularly excited to share our latest show: Basis PointsListen to the podcast (Apple | Spotify)Watch on YouTubeRead the monthly email———In the spirit of reconciliation, Equity Mates Media and the hosts of Equity Mates Investing acknowledge the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respects to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander people today. ———Equity Mates Investing is a product of Equity Mates Media. This podcast is intended for education and entertainment purposes. Any advice is general advice only, and has not taken into account your personal financial circumstances, needs or objectives. Before acting on general advice, you should consider if it is relevant to your needs and read the relevant Product Disclosure Statement. And if you are unsure, please speak to a financial professional. Equity Mates Media operates under Australian Financial Services Licence 540697. Hosted on Acast. See acast.com/privacy for more information.

  Chronic kidney disease now affects nearly 850 million people worldwide, yet early detection and simple, evidence-based interventions can dramatically change the trajectory of both kidney and cardiovascular health.

In Part 1 of this 3-part series, New York Times bestselling fitness author and celebrity trainer Jorge Cruise reveals why “physical hunger” is often not real hunger at all.Most people blame willpower. Or they assume the only answer is a GLP-1 drug. But the truth is simpler — and more fixable: mineral deficiency.When your body runs low on key minerals, hunger signals get dysregulated. That can trigger constant cravings, “snack attacks,” and overeating — even when you've had enough food.In this episode, Jorge explains the 3 minerals tied to hunger regulation:• Sodium (salt)• Magnesium• PotassiumThis is all leading to a FREE 90-minute live Zoom event where Jorge will teach his approach, including “Zero Hunger Water,” and how to shut down physical hunger naturally.https://us06web.zoom.us/j/83964851796?pwd=h6aVopb3X3cdy3b0j60nmwbADGarC7.1COMING NEXT• Part 2 (Saturday): Emotional Hunger • Part 3 (Sunday): Restore Lean Muscle FREE LIVE EVENT (SIGN UP)Monday, December 8th — 5:00 PM Pacific (Live on Zoom)To get the invite and all details, join the email list here:https://www.jorgecruise.com/p/welcome-to-the-revolutionWEBSITE JorgeCruise.com FOLLOW ON INSTAGRAMhttps://www.instagram.com/jorgecruisecoachingHandle: @jorgecruisecoachingSHARE THIS EPISODEIf someone you love struggles with cravings, overeating, belly fat, or “always being hungry,” send them this. Physical hunger isn't what most people think — and the fix is not what they've been told.(Disclaimer: This content is for educational purposes and is not medical advice.)

Operativo “Catahoula Crunch” causa pánico en comunidades.Pausan trámites migratorios para 19 países con restricciones.La OMS pide regular y ampliar accesos a medicamentos GLP-1.Estudios revisan si es necesario vacunar contra hepatitis B al nacer.Llegan vuelos con más de 500 venezolanos de México y Estados Unidos.Ponte al día con lo mejor de ‘La Edición Digital del Noticiero Univision' con Carolina Sarassa y Borja Voces.

This episode of The Better Life with Dr Pinkston features Dr Pinkston and Ray Solano from PD Labs, focusing on how to navigate and survive the holidays—dubbed the "Super Bowl of Sugar" (Halloween to Valentine's Day)—without derailing your health goals. The discussion centers on research challenging restrictive dieting, suggesting that unrestricted eating of nutritious food, layered with non-digestible fiber (nuts, seeds, berries) to slow sugar absorption, can offer similar benefits to fasting without the negative effects. Key Takeaways: Mindful Holiday Strategy: The holidays are a time for balance and not gaining weight, rather than focusing intensely on losing it. The Problem with Restriction: Restrictive diets (like extreme keto or carnivore) can backfire psychologically and physically. Research suggests high protein without proper carbohydrates can negatively affect longevity. The "Eat Human" Approach: Focus on a common-sense approach: avoid processed foods, know your intolerances, and aim for a balance of protein, fat, and carbs (suggested ratio: 40% protein, 30% fat, 30% carb) in every meal. Breakfast is Key: Start the day with high protein (40 grams) to stabilize blood sugars, reducing cravings later. Avoid traditional high-carb breakfasts like instant oatmeal. Stay Hydrated & Stress-Free: Managing stress with simple supplements like Magnesium Glycinate and Theanine (or cortisol managers like Triquillata) is crucial, as stress often leads to poor eating choices. Next-Generation Health: Ray Solano introduces PD Labs' work on peptides (like the GLP-1 incretins) and their innovative two-year project to make these high-molecular-weight molecules available transdermally (non-injectable) by Christmas, transforming chronic disease prevention. The conversation emphasizes starting your health recovery journey now, not waiting for a "magical time" in January.See omnystudio.com/listener for privacy information.

Shannon returns to discuss perimenopause, GLP-1s, and Hashimoto's. She and Scott navigate the challenges of raising a teen with T1D and ADHD while preparing for adulthood. Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Tandem Mobi ** twiist AID System Drink AG1.com/Juicebox Use code JUICEBOX to save 40% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

Franklin The Turtle was co-opted by Team Trump and now our childhoods are ruined. We've all reached our breaking point with Ticketmaster but Olivia Dean did something about it. Whales are being given breathalysers and don't even want to talk to a lawyer first. Ozempic is about to go generic in Canada - so are all the GLP-1 drugs, aka “gotta lose pounds” shots. Gavin Crawford quizzes comedians Martha Chaves, Alice Moran and Craig Lauzon about what happened in the news this week. If you're too afraid to share your opinions on social media, that's okay! Fill out this listener questionnaire instead: www.cbc.ca/BecauseSurvey

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big FDA recall around Freestyle Libre (see more below to find out if you're affected), Dexcom launches their 15.5 day sensor, Omnipod announces enhancements, Tandem tests a fully closed loop (with high fat, high carb meals) and lots more! Find out how to submit your Community Commercial Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. Our top story this week: XX Certain glucose monitors from Abbott Diabetes Care are providing users with incorrect glucose readings, an error that has been linked with the deaths of at least seven people and more than 700 serious injuries worldwide, according to an alert from the US Food and Drug Administration.   Incorrect glucose readings can lead to improper treatment. Abbott warned that about 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors are affected, but no other Libre products. Patients can visit FreeStyleCheck.com to see if their sensors are affected and to get a replacement for free.   The FDA has also published specific information about the affected products in its alert. The agency considers this to be a "potentially high-risk issue" and will continue to update its website as information becomes available.   "Patients should verify if their sensors are impacted and immediately discontinue use and dispose of the affected sensor(s)," the FDA said.   https://www.cnn.com/2025/12/02/health/abbott-diabetes-glucose-monitors https://www.freestylecheck.com/us-en/home.html XX Omnipod 5 is getting some enhancements.. and Omnipod 6 is announced. The FDA cleared updates including  a lower, 100 mg/dL target glucose option and what they call a more seamless automated experience. "This is the most significant algorithm advancement to our Omnipod 5 System since its launch in 2022," said Eric Benjamin, Insulet EVP and COO. Insulet said the new 100 mg/dL target glucose expands Omnipod 5's customization range. It now features six settings between 100 mg/dL and 150 mg/dL in 10 mg/dL increments. The company said this flexibility allows healthcare providers to tailor insulin delivery more precisely. It supports individuals seeking tighter glucose management or aiming to meet specific glucose goals. Omnipod 5's latest upgrades also help users stay in "Automated Mode" with fewer interruptions, even during prolonged high glucose events. Insulet plans to launch the updates to the algorithm in the first half of 2026. The company announced plans for an Omnipod 6 – without a lot of detail - at the company's Investor Day event in November. They also talked about a new, fully closed-loop pump for the type 2 diabetes population. https://www.drugdeliverybusiness.com/insulet-fda-clearance-omnipod-5-algorithm-enhancements/ XX Dexcom, the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System will launch in the United States on Dec. 1, making it the longest-lasting CGM system with 15.5 days of wear.   Dexcom G7 15 Day will first be available through durable medical equipment (DME) providers on Dec. 1 with full retail launch in the coming weeks. Dexcom G7 15 Day will also be covered for Medicare beneficiaries.   Dexcom G7 15 Day's industry-leading wear-time will provide fewer sensor changes, less disruption and more time for people with diabetes to benefit from life-changing CGM technology.   New with Dexcom G7 15 Day:  Longest lasting CGM system with 15.5 days of wear. Best-in-class accuracy1 with an overall MARD of 8.0%. Easier glucose management with fewer monthly sensor changes and reduced monthly waste. This follows yesterday's announcement – the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults 18 and older with Type 2 diabetes using long-acting insulin. Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as directed by their healthcare provider. At launch, Dexcom G7 15 Day will connect with the iLet Bionic Pancreas and Omnipod® 5§§. We are working closely with Tandem and look forward to extending the launch to their customers shortly as they finalize integration. For specific information on pump compatibility and availability with the Dexcom G7 15 Day system, visit Dexcom.com/connectedpumps https://investors.dexcom.com/news/news-details/2025/Dexcom-G7-15-Day-Continuous-Glucose-Monitoring-System-to-Launch-on-Dec--1-in-the-United-States/default.aspx   XX A small study of ten adults with type 1 diabetes tested Tandem's new fully closed-loop "Freedom" insulin system — and the participants put it through a real-world stress test. For 72 hours in a hotel setting, they ate heavy carb-and-fat meals, skipped all meal announcements, and didn't give any mealtime insulin boluses. The system handled almost everything automatically. Researchers said the device stayed in closed-loop mode 97% of the time and there were no incidents of diabetic ketoacidosis or severe hypoglycemia reported. While using the Freedom system, participants spent a median 61% of the day in the glucose target range — slightly higher than the 56% achieved with their usual pump at home. But the biggest improvement came overnight: time in range jumped to 96% with the closed-loop system compared to just under 70% during their home-pump week. With almost zero time spent below 70 mg/dL, researchers concluded that the fully automated Tandem system was both safe and effective even with unannounced, high-impact meals — hinting at a future of diabetes management that demands less effort from users.   XX Novo Nordisk reported promising mid-stage results for its experimental drug amycretin (AM-ee-creht-in) in diabetes patients on Tuesday. Amycretin, targets both GLP-1 and amylin hormones. In this study, it helped patients with type 2 diabetes lose up to 14.5% of their body weight over 36 weeks with weekly injections, far outperforming a placebo. The oral version delivered weight loss of up to 10.1%. Rival Eli Lilly  is surging ahead with its own amylin-based drug, eloralintide, which is advancing to late-stage testing after helping patients shed as much as 20% of their weight in a mid-stage trial. https://www.cnbc.com/2025/11/25/novos-next-gen-obesity-drug-shows-positive-results-heads-to-late-stage-testing.html XX The U.S. Medicare health plan said on Tuesday that newly negotiated prices for 15 of its costliest drugs will save 36% on those medications compared with recent annual spending, or about $8.5 billion in net covered prescription costs. The prices go into effect in 2027, including a monthly price of $274 for Novo Nordisk's popular GLP-1 drug semaglutide, sold as Wegovy for weight loss and Ozempic for diabetes. medicare's recent net price for Ozempic, opens new tab was $428 a month, according to an analysis published in the Journal of Managed Care and Specialty Pharmacy. Medicare put the drug's list price, before confidential rebates and discounts, at $959 a month. Based on such nondiscounted list prices, Medicare said savings on the 15 drugs ranged from 38% to 85%. The annual price negotiations were established under President Joe Biden's signature Inflation Reduction Act (IRA) of 2022. Previously, Medicare was barred by law from negotiating with drugmakers. https://www.reuters.com/business/healthcare-pharmaceuticals/us-negotiated-medicare-prices-15-more-drugs-test-cost-savings-promise-2025-11-25/   XX LifeScan announced its Chapter 11 bankruptcy reorganization plan received U.S. Bankruptcy Court approval. LifeScan said it's positioned to emerge from its financial restructuring process by the end of the year. The CEO says, "This balance sheet restructuring provides a stronger foundation for LifeScan to support our base business, advance new growth strategies, and commence our journey to become one of the most comprehensive players in the glucose management space." https://www.drugdeliverybusiness.com/glucose-monitor-lifescan-emerge-from-bankruptcy/ XX An artificial intelligence (AI)-led Diabetes Prevention Program (DPP) was as effective as a traditional human-led program in achieving recommended goals for weight loss, A1c reduction, and physical activity, according to a randomized trial of adults with prediabetes and overweight or obesity. One example of a push notification: "Looks like you're at the grocery store, Rita! Want a quick list of high-fiber snacks or smart swaps to stay on track this week?" The app also provided location- and goal-based education, with gamification elements to promote engagement. Approximately one third of participants in both the AI and human-led groups achieved the primary outcome (31.7% and 31.9%, respectively). Results were consistent across sensitivity analyses and individual components of the composite endpoint. "As more AI-based programs emerge, head-to-head comparisons among different AI-DPPs will be informative. An AI-led approach will not suit everyone; some individuals benefit more from human interaction and accountability," said Mathioudakis, adding that future research should focus on best matching patients to the modalities they prefer. https://www.medscape.com/viewarticle/ai-directed-diabetes-prevention-program-effective-human-2025a1000xam XX A new study suggets metformin could help people with type 1, reducing the need for insulin.  The researchers were surprised to find that metformin did not improve insulin resistance or change blood sugar levels. This suggests that, unlike in type 2 diabetes, metformin doesn't combat insulin resistance in type 1 diabetes.   However, metformin did reduce the amount of insulin people needed to keep their blood sugar levels stable.   https://www.the-express.com/news/health/192157/diabetes-medicine-insulin-type-1 XX Beyond Type 1 launches #TheBeyondType campaign in India to combat type 1 diabetes stigma. Nick Jonas is one of the founders of Beyond Type 1, his wife, Priyanka Chopra Jonas is his partner in this new non profit. The initiative highlights inspiring individuals living with T1D and partners with local organisations to improve awareness, medical support, and community networks for affected families across the nation. India has more young people living with T1D than any other nation, yet understanding of the condition remains limited. Beyond Type 1 is partnering with grassroots organisations across high-need regions. These include HRIDAY in Delhi–NCR, Nityaasha Foundation in Pune, Gram Jyoti in Jharkhand, and SAMATVAM Trust in Bangalore—each group focusing on improving awareness, providing medical support and building stronger community networks for young people with T1D.

Program notes:0:35 Update on RSV, flu and COVID-19 vaccines1:35 500 studies included2:35 Rare myocarditis3:35 Flu vaccine in older adults4:30 Tai chi or CBT-I for chronic insomnia5:30 Trained in one or the other6:30 Inexpensive and accessible7:30 $150 billion cost of chronic insomnia7:45 GLP-1s and WHO guidance8:50 Multimodal approach required9:45 Prevention is important9:55 Corticosteroids in pregnancy10:50 1.3 million pregnancies11:50 Used for multiple indications12:46 End

Episode 93 of Astonishing Healthcare features Susana Villegas Spillman, who brings over 20 years of health benefits plan management experience to the studio for a discussion about what works, what's broken, and what employer plan sponsors deal with day in and day out. This “unfiltered perspective” from the plan sponsor's seat is welcome and timely. If you're one of the increasingly large percentage of benefits directors, CHROs, CFOs, et al. out there looking to transition from a traditional benefits experience to a new, transparent, aligned, unified model, this episode is for you!Susana explains how a fragmented system fails members, and while we've evolved from the default “call the number on the back of the card” - which directs you to the emergency room - point solutions create more silos, and data is too scattered and stale to drive meaningful change. This forces employers to take control, which leads to her “most astonishing thing,” which is a critical reminder for every benefits leader: “Know what's in your contracts.”Episode 93 covers:The importance of centering the strategy around long-term goals and member experience (with ruthless accountability).The upside of unbundling services from carriers and using independent navigation partners to guide members to high-quality care; why culture fit and flexibility matter when evaluating vendors.Why qualitative measures of success offer a better gauge of program effectiveness vs. empty promises of ROI.The evolving role of benefits consultants, and how to evaluate consultant relationships.The outdated RFP processes and how to run a better RFP.GLP-1 coverage for weight loss.Related ContentHealth Benefits 101: The Importance of a Transparent PBM ModelWhy this benefit leader switched to a more modern, transparent PBMReplay - Unifying Medical and Pharmacy Benefits: The Blueprint for Better Employee Health and WellnessAH078 - More About Judi Health™ & the Unified Benefits Experience, with Dr. Sunil Budhrani and Mike TateCheck out our Health Benefits 101 ContentFor more information about Capital Rx and this episode, please visit Judi Health - Insights.

In this episode of Healthy Mom Healthy Baby Tennessee, Dr. Linley Wolfe interviews Dr. Carrie Brackney, a maternal-fetal medicine physician in Memphis, about GLP-1 receptor agonist medications (commonly known as Ozempic, Wegovy, and similar drugs) and their implications for pregnancy. The discussion covers how these medications work, their dramatic effects on weight loss and diabetes management, and the emerging phenomenon of "Ozempic babies" - unintended pregnancies occurring in women taking these medications. Dr. Brackney provides guidance on when to discontinue these medications before conception, discusses limited safety data in pregnancy, and explains what monitoring is recommended for women who become pregnant while taking GLP-1s. Both physicians share their personal experiences with these medications and express hope for future research on postpartum use.Episode Highlights00:00:04: Welcome to Healthy Mom, Healthy Baby Tennessee podcast, brought to you by the Tennessee Initiative for Perinatal Quality Care (TIPQC), which exists to improve health outcomes for mothers and infants in Tennessee 00:00:46: Dr. Linley Wolfe introduces Dr. Carrie Brackney, a maternal-fetal medicine physician in Memphis who has been practicing as a perinatologist for three years after working as a general OB-GYN for nine years00:01:32: Dr. Brackney describes her passion for caring for women with complex pregnancies and helping them find joy during challenging times00:02:03: Dr. Wolfe introduces the topic of GLP-1 medications, noting they have been revolutionary for people struggling with weight00:02:38: Dr. Brackney explains that GLP-1 receptor agonists work by activating glucagon-like peptide one receptors, regulating blood sugar, reducing appetite, and slowing digestion through multiple mechanisms00:03:46: Discussion of how GLP-1 medications have been around for diabetes treatment but have been increasingly used for weight loss over the last four to five years00:04:04: Dr. Brackney notes these medications are also being used for patients with cardiovascular conditions and kidney disease, showing decreased complications00:04:28: Dr. Wolfe mentions recent approval for people who are overweight with sleep apnea, predicting more indications will emerge00:04:42: Cost identified as one of the biggest barriers to these medications becoming more popular00:05:01: Dr. Brackney reports that semaglutide and tirzepatide show potential for over 10% weight loss, while liraglutide shows 5-15% total weight loss00:05:49: Discussion of side effects, with nausea and constipation being the most common, though they are treatable and many people adjust over time00:06:09: Dr. Wolfe asks about common brand names versus generic names for listener clarity00:06:25: Dr. Brackney lists brand names including Ozempic, Wegovy, Rybelsus (semaglutide), Trulicity (dulaglutide), Victoza and Saxenda (liraglutide), and Mounjaro (tirzepatide)00:07:02: Discussion of compounded medications versus manufacturer medications, with Dr. Brackney noting compounded versions are not FDA-regulated and therefore not considered as safe00:07:55: Dr. Wolfe transitions to discussing pregnancy and the phenomenon of "Ozempic babies"00:08:51: Dr. Brackney explains that obesity reduces fertility, with obese women having three times higher risk of infertility and 40% higher miscarriage rates00:10:28: Discussion of how GLP-1 medications may interfere with contraceptive distribution in the body due to slowed gastric emptying00:11:04: Dr. Wolfe summarizes that better overall health, weight loss, and potential contraceptive interference all contribute to "Ozempic babies"00:11:27: Dr. Brackney recommends discontinuing GLP-1 medications at least one to two months before trying to get pregnant, noting limited data on ideal timing00:12:38: Discussion of the lack of...

Knowing little or next to nothing about GLP-1, Ron does a show about it..... Guest: Author Shawn Wells "The Energy Formula"

Are bioidentical hormones really linked to living longer and feeling better as you age? In this video, Dr. Mok explains the connection between bioidentical hormones and longevity, and why the goal isn't just more years of life, but more years of feeling healthy, active, and yourself. We walk through how menopause and declining hormones can influence cardiovascular health, bone density, weight, mood, cognition, and sexual wellness, and how hormone replacement therapy may support both lifespan and healthspan when used appropriately. You'll also hear the difference between synthetic hormones and bioidentical hormones, and why working with a provider who understands prevention and wellness, not just disease management, can change the conversation around aging. If you're wondering whether hormone therapy is right for you, this video will help you understand the potential benefits, risks, and questions to discuss with your doctor. Our approach at Allure Medical focuses on evidence-informed care, individualized dosing, and supporting the whole person, not just lab numbers. Timestamps:00:00 — Do Hormones Really Help You Live Longer? 00:18 — Bioidentical Hormones and Longevity Explained 00:45 — Lifespan vs Healthspan: What Really Matters 01:10 — WHI Study, Confusion, and the Drop in Hormone Use 01:40 — Healthcare vs Wellness: Treating Disease vs Preventing It 02:05 — Menopause, Weight Gain, GLP-1s, and Underlying Causes 02:35 — How Estrogen and Testosterone Affect Body Composition 02:55 — Mood, Sexuality, Skin, and Quality of Life Benefits 03:20 — Should You Consider Bioidentical Hormones? Talk to Your DoctorLearn More: https://www.alluremedical.com/Books & Research: https://www.alluremedical.com/books/Follow Dr. Charles Mok & Allure Medical: LinkedIn: https://www.linkedin.com/in/charles-mok-4a0432114/ Instagram: https://www.instagram.com/alluremedicals/ YouTube: https://www.youtube.com/@AllureMedical TikTok: https://www.tiktok.com/@alluremedicalAmazon Store: https://www.amazon.com/stores/Dr.-Charles-Mok/author/B0791M9FZQInner Circle Membership: https://www.alluremedical.com/inner-circle-membership/Subscribe to the show & leave a 5-star review!#insidethecure

Send us a textBrown, sulfur-smelling water stamped “healthy” by the lab was the wake-up call: legal doesn't always mean safe. We sit down with water treatment expert Sidian Kaufman to unpack the gulf between regulatory limits and what's best for long-term health, and we map out practical, affordable steps to turn your tap into a trusted source—no plastic bottles required.Sidian explains the EPA's MCL (Maximum Contaminant Level) versus MCLG (health-based goal) and why the “feasible” standard can leave you drinking water that technically passes while still carrying avoidable risk. We share gripping real-world stories, including a shallow-well household dealing with cryptosporidium that standard tests missed, and a city water case where a spike in chlorine byproducts—like dibromochloromethane—coincided with serious concerns. These moments reveal how chronic, low-level exposures often fly under the radar and why targeted testing and tailored filtration change outcomes.We also tackle microplastics and nanoplastics—the everywhere problem that turns bottled water into a Trojan horse. With studies estimating tens of thousands of particles per liter in bottled water, we focus on practical defense: reverse osmosis under the sink for drinking and cooking; nanofiltration or ultrafiltration for whole-home protection; and simple behavior shifts like using stainless steel or glass bottles and avoiding heat-cycled plastics. Along the way, we dig into skin and hair issues tied to hardness, how to prioritize a real test panel (metals, VOCs, chlorine byproducts, PFAS), and why builders are starting to make filtration standard in new homes and remodels.If you've wondered whether your water is truly serving your health, this conversation gives you a clear roadmap: test smarter, filter where it counts, and carry clean water without plastic. Subscribe, share this with a friend who still buys bottled, and leave a review with your biggest water question—we'll answer it in a future episode. Support the show Sponsor Affiliates Empowering Your Health https://www.atecam.com/ Get YOUR Own Joburg Protein Snacks Discount Code: Damaris15 Or Damaris18 Feeling need to Lose Weight & Become metabolically Healthy GET METABOLIC COURSE GLP 1 REseT This course is designed for individuals looking to optimize their metabolic health through integrative and functional medicine approaches. Whether you're on a GLP-1 medication or seeking natural ways to enhance your metabolic function, this course provides actionable steps, expert insights, and a personalized roadmap sustainable wellness. Are you feeling stressed, tired, or Metabolism imbalanced? Take advantage of our free mindful steps to help improve your well-being.ENJOY ONE OF our Books Mindful Ways Health Wealth & Life https://stan.store/Mindfullyintegrative Join Yearly membership ALL IN ONE FUNCTION HEALTH Ask Us for help...

Everyone's talking about GLP-1s, but no one's REALLY talking about them.In this raw, real, and refreshingly honest mini, Susan Robbins sits down with fellow pH360 coach Lisa St. Ledger to unpack what's really going on with the weight-loss drug craze, the good, the bad, and the misunderstood.From the explosion of prescriptions to the deeper emotional and physiological patterns behind weight gain, Susan and Lisa explore the conversation most people aren't having.This episode pulls back the curtain on personalized health, epigenetics, and why “doing all the right things” doesn't always work. Whether you're on a GLP-1, considering one, or just curious about what's really driving today's health trends, this one will get you thinking.In this episode:The truth behind the GLP-1 boom (and why doctors are handing them out like candy)The surprising differences between microdosing and standard dosingLearn More about Lisa St. Ledger:Accredited Health & Wellness Coach | Endorsed PH360 Health Coach | Advocate for Lasting Health TransformationWith over 28 years of experience as an educator, I have witnessed how knowledge, empowerment, support, and fostering self-efficacy can create lasting change. As an Accredited Health and Wellness Coach, my mission is to guide individuals on their unique health journeys, helping them unlock their full potential by tapping into their personal epigenetics using the PH360 platform.Over the past decade, I have faced significant health challenges, including a diagnosis of Hashimoto's thyroid disease and surviving breast cancer. These experiences have given me a deep understanding of the emotional and physical toll that chronic health conditions can take. They have also strengthened my resolve to help others overcome their own obstacles, reclaim their health, and live vibrantly.Outside of my work, I find joy in activities that nurture both my body and soul. I love cooking healthy meals, hiking in nature, and oil painting, which allows me to express my creativity and find peace. These passions help me stay balanced and connected to what matters. I'm honored to support others in achieving lasting health transformation and guiding them toward a life of vitality.RESOURCES:Connect with Lisa St. Ledger:Website: https://resolutionhealth360.com/Show notes: https://healthyawakening.co/2025/12/05/episode98Visit the website: healthyawakening.co/podcastFind listening links here: https://healthyawakening.co/linksConnect with Susan:Check out Susan's NEW E-book! Download it FREE here: https://healthyawakening.co/ebook-signupContact me for your DNA testing or epigenetic coaching! To schedule a FREE Personalized Health Strategy Session, send an email to susan@healthyawakening.coFacebook: https://www.facebook.com/susanrobbinshealthyawakeningInstagram: @susanrobbins_epigeneticcoachSusan's LinkTree: https://linktr.ee/susanrobbinsConnect with Kate King:Kate's Website: https://TheRadiantLifeProject.comKate's Linktree: https://linktr.ee/theradiantlifeprojectP.S. Want reminders about episodes? Sign up for our newsletter, you can find the link on our podcast page! https://healthyawakening.co/podcast

Welcome to vlogmas sloots! Our December episodes will all be filled w/ holiday cheer including but not limited to gift guides, getting drunk off holiday drinks, making snowflakes and more. This week we're decorating my mini tree and finally recapping my SKIMS shoot! enjoy xoxo  Follow Sofia on:  Instagram - https://www.instagram.com/sofiafranklyn   TikTok - https://www.tiktok.com/@sofiafranklyn   Twitter - https://twitter.com/sofiafranklyn    Threads - https://www.threads.net/@sofiafranklyn  To learn more about listener data and our privacy practices visit: https://ww.audacvinc.com/privacy-policy   Go to https://www.ro.co/Sofia to see if your insurance covers GLP-1s—for free. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Scott and Dave Knapp break down GLP-1 medications, weight loss, metabolic health, inflammation, type 1 impacts, myths, microdosing, and why these drugs may reshape diabetes care. Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Tandem Mobi ** twiist AID System Drink AG1.com/Juicebox Use code JUICEBOX to save 40% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!

Bob's Movie Club is diving head first into Christmas with ‘Love Actually.' Plus, we're sneaking in a bonus movie the following week! If you want to take the kids to the theater, Jim Carey's ‘Grinch' is being re-released for its 25th anniversary. Plus, the long awaited Timothée Chalamet movie opens on Christmas day. Not feeling the Christmas spirit? Here's how to get yourself in the mood! A survey found that GLP-1 users will be skipping their dose to enjoy Christmas snacks. Rediscover the rabbit holes you fell down this year: YouTube now has an end of year recap of what you've watched. Are Sarah & Vinnie in your Spotify Wrapped? TV is hotter than ever. Here's how to get the most out of ‘Stranger Things' final season. Lisa Kudrow is BACK in ‘The Comeback' following a 20 year hiatus. The next ‘Game of Thrones' prequel is premiering in January! It's National Cookie Day - as if we needed a reason. PSA: Doctors are important. Are your kids getting an allowance? Here's how much other parents are dishing out. Death is not an option! Sarah's torture continues. TMZ talked to Tara Reid following her hospitalization. The kids are still obsessed with 6/7, but Sarah knows how to stop the madness! JRR Tolkien's desk reminds Vinnie of his desk growing up. He's still recovering from his brother gaslighting him. Plus, fast facts and tantalizing tangents. The best Christmas songs of all time… debatable. Let's discuss! Congratulations Bad Bunny on being the #1 most listened to artist of 2025. Taylor Swift is still #1 in our hearts. Tonight's the night: don't forget your moon juice! Church pastors are using Chat GPT to write their sermons. Plus, an unlikely advertisement for BIC, and a spirited game!

Bob's Movie Club is diving head first into Christmas with ‘Love Actually.' Plus, we're sneaking in a bonus movie the following week! If you want to take the kids to the theater, Jim Carey's ‘Grinch' is being re-released for its 25th anniversary. Plus, the long awaited Timothée Chalamet movie opens on Christmas day. Not feeling the Christmas spirit? Here's how to get yourself in the mood! A survey found that GLP-1 users will be skipping their dose to enjoy Christmas snacks. Rediscover the rabbit holes you fell down this year: YouTube now has an end of year recap of what you've watched. Are Sarah & Vinnie in your Spotify Wrapped? Tag Alice!

In this episode, Dr. Thomas Hemingway shares how Gut Health is one of the Most Powerful Tools we can Access to Increase our Energy, Fitness and Overall Well-being and Health; Hippocrates said, "All Disease Begins in the Gut," and Dr. Thomas shares, "All Health and Healing Begins in the Gut."Have a Listen and SHARE with a friend!**JOIN DR. HEMINGWAY LIVE in-person at ALIGN AWAKEN!  Event in San Diego Jan 22-25, 2026!*ACCESS my FREE workshop, "Younger, Stronger, for Longer!"  How to turn back your biological age 10-20 years so you can do the things you want to do that you no longer thought possible due to your age.  Perform at your best and live your best life!*And, in my new Performance, and Longevity medical practice we specialize in turning back your biological age and OPTIMIZING HORMONES so you can feel a decade or more younger so you can do the things you want to do that you thought were no longer possible due to your age.  Join the waitlist here!*SHARE with a Friend and please drop a Review:)*Don't wait to Prioritize your health, Start Today with the Simple and Powerful Steps detailed in my Best-selling book.*GET DIRECT ACCESS to DR. HEMINGWAY in these AMAZING COURSES!**Free resource: 'The truth about GLP-1s and their alternatives' - https://drthomashemingway.myflodesk.com/n1yyjkcb68Mahalo and Aloha andTo your health,

I was out drinking martinis with Cora Opsahl, director of 32BJ Health Fund, and Cora said, "Look, most plan sponsors' biggest expense is health system spend, hospital spend." I know this is an unexpected start to an episode about pharmaceutical pricing and value featuring Sarah Emond, CEO of ICER (Institute for Clinical and Economic Review). But yeah, 50% of most plan sponsors' spend these days goes to health systems. Fifty percent! One half! For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. So, if a patient who is adherent to a drug and that drug keeps that patient out of the hospital, why do I want to make a patient have excessive skin in the game to get that drug, which everybody knows at this point this "skin in the game" can cause said patient to not be adherent in many cases, cost being a very big reason patients give for not taking medications as prescribed. So then we have this not adherent patient who winds up in the hospital, via the ER often enough. The core issue here that surfaced, bottom line—and I'm not sure if this was in spite of the martinis or as a result of them—but while hospital spend is the largest health expense, high-value drugs that prevent hospitalization often face patient cost sharing and access restrictions, which leads to poor patient adherence and ultimately higher system cost potentially. So then Cora and I spent the next half hour debating when the statement is empirically true and when it's not. And you know what it all boils down to? What's the value of the drug? Do we even know what that means to start? But if it's determined that the drug is relatively high value, then the plan desperately should want to do everything possible to keep that patient on that medication, and cost sharing is a huge barrier to adherence. Today, as I said, I'm speaking with Sarah Emond, CEO over at ICER, and we get into all of this in the conversation that follows. In fact, most of the conversation that follows explores the tensions that exist in the current way that we sell and buy pharmaceutical products. I'm just gonna sum up these tensions in a list here at the top of this show. There's six of them that Sarah Emond and I discussed today by my counting, and each of these we explore in some depth. So, here's the list. Tension 1: The value of any given drug (in other words, what is the fair price for that drug considering the health gains that it delivers) versus the total cost to the plan for the total population taking that drug. GLP-1s have entered the chat. GLP-1s (by ICER's analysis, at least) are super high-value drugs that also can bankrupt plans due to the number of folks who may benefit from taking the drug. Definitely a tense tension to kick off our list here. Tension 2: The list or net price of a drug versus patient access and affordability. Again, this can be tense in an area of much misalignment. You can have a great well-priced drug with huge patient affordability and access challenges because drug net price and coinsurance amounts often have nothing to do with each other. Tension 3: Lifetime value of a drug versus a 3-, 2.5-year, whatever time horizon that many plan sponsor actuaries use in their value assessment. We discussed this today, but there's a Summer Short (SUMS7) on actuarial value horizons with Keith Passwater and JR Clark if you wanna dig in on this further. Tension 4: The tension between the societal value of a drug or even the patient's perceived value of a drug versus what an employer plan sponsor might perceive as the value. What is the formula used to determine value? What's in and what's out? So, that's a bigger conversation just beyond the time horizon for what's included in this calculation. Tension 5: Exacerbating the what's included in the value contemplation beyond just what you include in there is the tension between what is hypothetically of value and what is possible to measure. If you have pharma datasets and medical datasets separate in silos, who knows how many hospital readmissions were prevented by whatever drug? And how much presenteeism or absenteeism exists. I mean, it is an outlier, again, if anyone even knows the net price they paid for a drug, just to level set context here. Tension 6: Lowering financial barriers for patients to take drugs that are of value versus status quo goals and incentives. Like, for example, PBMs (pharmacy benefit managers) are often told that their goal is to reduce drug spend. Okay … so, how do I do that? Oh, reduce access either by prior auths or delay tactics or really high coinsurance, which is gonna reduce adherence by design. And it's someone else's problem—if I'm just thinking like a status quo PBM—if medical spend goes up, right? So, that's our last and not insignificant tension. And look, who comes out the loser in all of these tensions when they get tense? Patients. Not pricing based on value and not buying and setting up cost sharing based on value punishes patients and also plan sponsors or any other ultimate purchaser in the long term, given that the plan is but a population of patients if you start thinking about it in that context. Here is Sarah's advice in a nutshell: Pharma, sell. Pick your price based on something other than market power. And some pharma companies are actually dipping their toe into these waters and doing it. But then PBMs and plan sponsors have to hold up their end of the bargain here and buy drugs based on their value, not just the size of their rebates or some other discounting promise. And then we gotta continue the through line through to member affordability and access. High-value drugs should get preferred. So, right, do a high-value formulary. Listen to the show with Nina Lathia, RPh, MSc, PhD (EP426) on high-value formularies and then listen (after you're done with that one) to episode 435 with Dan Mendelson entitled "Optimized Pharmacy Benefits Are Required if You Want to Do or Buy Value-Based Care." Also, as I said, GLP-1s come up in this conversation, so … yeah, buckle up. One last thing, besides my normal thank you to Aventria Health Group for sponsoring this episode, I am so pleased to thank Payerset for donating to help Relentless Health Value stay on the air. Payerset is a price transparency company with a mission to create fair and equitable healthcare for everyone. Love that. Payerset empowers healthcare organizations, employers, and patients with the most complete set of healthcare price transparency data. They benchmark every negotiated rate and claim and delivering the actionable insights needed for smarter contract negotiations and a more transparent healthcare system. As I have said several times today, my conversation is with Sarah Emond, CEO of ICER. Also mentioned in this episode are Institute for Clinical and Economic Review (ICER); Cora Opsahl; 32 BJ Health Fund; Keith Passwater; JR Clark; Nina Lathia, RPh, MSc, PhD; Dan Mendelson; Aventria Health Group; Payerset; Antonio Ciaccia; Elizabeth Mitchell; Purchaser Business Group on Health (PBGH); Shane Cerone; Sam Flanders, MD; Mark Cuban; Morgan Health; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here. You can learn more at ICER.org and follow Sarah on LinkedIn.   Sarah K. Emond, MPP, is president and chief executive officer of the Institute for Clinical and Economic Review (ICER), a leading nonprofit health policy research organization, with 25 years of experience in the business and policy of healthcare. She joined ICER in 2009 as its first chief operating officer and third employee and has worked to grow the organization's approach, scope, and impact over the years. Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston. A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor's degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based healthcare.   08:18 Why list prices are a lie. 10:59 How does the rebate model sometimes get in the way of paying for value? 12:50 Bonus clip with Sarah Emond. 13:14 EP491 with Elizabeth Mitchell. 13:20 EP490 and EP492 with Shane Cerone and Sam Flanders, MD. 14:37 The tension that is created between affordability and adherence. 15:03 When cost sharing makes sense in pharmaceutical drug pricing. 17:26 INBW42 with Stacey on moral hazard. 18:53 How GLP-1s are "wildly cost effective." 21:32 Why the sticker shock on cost-effective drugs is a failure in the system for paying for value. 22:38 ICER's report on GLP-1s. 26:59 EP385 with Dan Mendelson. 28:57 How employers and payers can have a value assessment approach and a health insurance system that allows access to cost-effective drugs. 29:48 How cost-effective prices are calculated. 31:55 One of the core value underpinnings for value assessment of drugs. 34:54 Why manufacturers and pharmacy benefit managers should work together more by referencing something like an ICER report. 36:55 EP426 with Nina Lathia, RPh, MSc, PhD. 38:21 "We can make different choices."   You can learn more at ICER.org and follow Sarah on LinkedIn.   @sarahkemond discusses #pharmaceutical #drugpricing on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW43), Olivia Ross (Take Two: EP240), John Quinn, Dr Sam Flanders and Shane Cerone (EP492), Elizabeth Mitchell (EP491), Shane Cerone and Dr Sam Flanders (Part 1), Dan Greenleaf (Part 2), Dan Greenleaf (Part 1), Mark Cuban and Cora Opsahl

This week on Two Parents & A Podcast we're deep in baby-name land — specifically the very important question: if you're only ever going to call a baby the nickname… why give them the long name?!

Pediatrician and mom, Dr. Chrissie Ott, chats about the use of GLP-1 meds in kids and teens.

In this episode, Jakob Emerson, Associate News Director at Becker's Healthcare, breaks down CMS' proposed 2027 Medicare Advantage rule, challenges facing smaller MA plans, and the shrinking access to GLP-1 medications on ACA marketplaces. He also highlights the evolving dynamics between payers, providers and consumers as policy and costs rapidly shift.

Sources tell CBS News a new Pentagon inspector general's report found Defense Secretary Pete Hegseth could have endangered American service members when he shared details of an active bombing mission in Yemen in March in a Signal group chat with other top officials and also mistakenly included a journalist. CBS News' Charlie D'Agata reports. President Trump pardoned Rep. Henry Cuellar before his trial even began. Cuellar, a Texas Democrat, and his wife will no longer face bribery and fraud charges. Scott MacFarlane reports. Former physician Salvador Plasencia will serve a 30-month sentence for his role in Matthew Perry's death. He pleaded guilty to supplying ketamine to Perry and his assistant in the weeks before the actor's October 2023 death. Some of Perry's family members spoke in court on Wednesday, with his sister telling Plasencia, "instead of protecting, you exploited." In the "CBS Mornings" series "Never Too Late," a 78-year-old woman finds a new purpose and passion for percussion. Now she's sharing the joy and health benefits of drum circles with fellow seniors. Experts say roughly six in 10 cats in the U.S. are carrying too much weight. A new clinical trial, "MEOW-1," could change that, testing to see if GLP-1 weight loss drugs can be used on pets. CBS News' Ash-har Quraishi reports. Lucy Liu talks about starring in and producing the movie "Rosemead," why she says the story resonates universally and reflecting on personal experiences for the film. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

In this episode of The Optimal Aging Podcast, host Jay Croft shares simple yet powerful holiday marketing ideas for gym owners and fitness professionals who serve clients over 50.From creative gift cards to recovery kits, Jay outlines 10 fitness-themed gift ideas that are easy to launch and designed to grow your business during the holiday season. You'll also hear how cross-promotion with local businesses can amplify your reach, and how to connect with GLP-1 users who've lost weight but aren't yet exercising.Whether you're looking for quick wins or long-term client growth, this episode is full of practical strategies to make fitness a meaningful gift this season — not just a transaction.

Gabby and I dive into the harmful narratives in how GLP-1's are marketed. The difference between food noise and hunger cues, and our thoughts on how we are discussing celebrities bodies these days. References:The Obesity Epidemic - Maintenance PhaseLaura Girard's Comments on *that* press tour Dietitians to follow if you're struggling: @your.latina.nutritionist@dietitiananna@all.bodies.nutrition@iamashantis@thenutritiontea@diet.culture.rebel@jaynemattingly

GLP-1 drugs that are commonly used to treat diabetes and obesity, like Ozempic and Wegovy – are in big demand. And they’re going to be more affordable. The Trump administration recently negotiated deals to lower the prices of these drugs. It seems like some details still need to be ironed out…. but from the looks of it, many Americans who use Medicare will be able to access GLP-1s at a fraction of their original cost. According to one of the deals, some Medicare patients will be able to get GLP-1s for a $50 copay. So it’s safe to assume as costs come down, these drugs are only going to get even more popular…. And we want to know more about them. In this latest “ask a doctor” segment, we’re asking two physicians to answer all of our burning questions. GUESTS: Dr. Scott Hagan, an associate professor of medicine at the University of Washington School of Medicine, who studies obesity. Dr. Mara Gordon, a family physician based in Philadelphia. She also writes about the culture of medicine and authors the “Real Talk With a Doc” column for NPR. RELATED LINKS: Medicare negotiated lower prices for 15 drugs, including 71% off Ozempic and Wegovy : Shots - Health News : NPR Ozempic is making me rethink how to be a body-positive doctor : Shots - Health News : NPR Thank you to the supporters of KUOW, you help make this show possible! If you want to help out, go to kuow.org/donate/soundsidenotes Soundside is a production of KUOW in Seattle, a proud member of the NPR Network.See omnystudio.com/listener for privacy information.

 If you're a scientist, and you apply for federal research funding, you'll ask for a specific dollar amount. Let's say you're asking for a million-dollar grant. Your grant covers the direct costs, things like the salaries of the researchers that you're paying. If you get that grant, your university might get an extra $500,000. That money is called “indirect costs,” but think of it as overhead: that money goes to lab space, to shared equipment, and so on.This is the system we've used to fund American research infrastructure for more than 60 years. But earlier this year, the Trump administration proposed capping these payments at just 15% of direct costs, way lower than current indirect cost rates. There are legal questions about whether the admin can do that. But if it does, it would force universities to fundamentally rethink how they do science.The indirect costs system is pretty opaque from the outside. Is the admin right to try and slash these indirect costs? Where does all that money go? And if we want to change how we fund research overhead, what are the alternatives? How do you design a research system to incentivize the research you actually wanna see in the world?I'm joined today by Pierre Azoulay from MIT Sloan and Dan Gross from Duke's Fuqua School of Business. Together with Bhaven Sampat at Johns Hopkins, they conducted the first comprehensive empirical study of how indirect costs actually work. Earlier this year, I worked with them to write up that study as a more accessible policy brief for IFP. They've assembled data on over 350 research institutions, and they found some striking results. While negotiated rates often exceed 50-60%, universities actually receive much less, due to built-in caps and exclusions.Moreover, the institutions that would be hit hardest by proposed cuts are those whose research most often leads to new drugs and commercial breakthroughs.Thanks to Katerina Barton, Harry Fletcher-Wood, and Inder Lohla for their help with this episode, and to Beez for her help on the charts.Let's say I'm a researcher at a university and I apply for a federal grant. I'm looking at cancer cells in mice. It will cost me $1 million to do that research — to pay grad students, to buy mice and test tubes. I apply for a grant from the National Institutes of Health, or NIH. Where do indirect costs come in?Dan Gross: Research generally incurs two categories of costs, much as business operations do.* Direct or variable costs are typically project-specific; they include salaries and consumable supplies.* Indirect or fixed costs are not as easily assigned to any particular project. [They include] things like lab space, data and computing resources, biosecurity, keeping the lights on and the buildings cooled and heated — even complying with the regulatory requirements the federal government imposes on researchers. They are the overhead costs of doing research.Pierre Azoulay: You will use those grad students, mice, and test tubes, the direct costs. But you're also using the lab space. You may be using a shared facility where the mice are kept and fed. Pieces of large equipment are shared by many other people to conduct experiments. So those are fixed costs from the standpoint of your research project.Dan: Indirect Cost Recovery (ICR) is how the federal government has been paying for the fixed cost of research for the past 60 years. This has been done by paying universities institution-specific fixed percentages on top of the direct cost of the research. That's the indirect cost rate. That rate is negotiated by institutions, typically every two to four years, supported by several hundred pages of documentation around its incurred costs over the recent funding cycle.The idea is to compensate federally funded researchers for the investments, infrastructure, and overhead expenses related to the research they perform for the government. Without that funding, universities would have to pay those costs out of pocket and, frankly, many would not be interested or able to do the science the government is funding them to do.Imagine I'm doing my mouse cancer science at MIT, Pierre's parent institution. Some time in the last four years, MIT had this negotiation with the National Institutes of Health to figure out what the MIT reimbursable rate is. But as a researcher, I don't have to worry about what indirect costs are reimbursable. I'm all mouse research, all day.Dan: These rates are as much of a mystery to the researchers as it is to the public. When I was junior faculty, I applied for an external grant from the National Science Foundation (NSF) — you can look up awards folks have won in the award search portal. It doesn't break down indirect and direct cost shares of each grant. You see the total and say, “Wow, this person got $300,000.” Then you go to write your own grant and realize you can only budget about 60% of what you thought, because the rest goes to overhead. It comes as a bit of a shock the first time you apply for grant funding.What goes into the overhead rates? Most researchers and institutions don't have clear visibility into that. The process is so complicated that it's hard even for those who are experts to keep track of all the pieces.Pierre: As an individual researcher applying for a project, you think about the direct costs of your research projects. You're not thinking about the indirect rate. When the research administration of your institution sends the application, it's going to apply the right rates.So I've got this $1 million experiment I want to run on mouse cancer. If I get the grant, the total is $1.5 million. The university takes that .5 million for the indirect costs: the building, the massive microscope we bought last year, and a tiny bit for the janitor. Then I get my $1 million. Is that right?Dan: Duke University has a 61% indirect cost rate. If I propose a grant to the NSF for $100,000 of direct costs — it might be for data, OpenAI API credits, research staff salaries — I would need to budget an extra $61,000 on top for ICR, bringing the total grant to $161,000.My impression is that most federal support for research happens through project-specific grants. It's not these massive institutional block grants. Is that right?Pierre: By and large, there aren't infrastructure grants in the science funding system. There are other things, such as center grants that fund groups of investigators. Sometimes those can get pretty large — the NIH grant for a major cancer center like Dana-Farber could be tens of millions of dollars per year.Dan: In the past, US science funding agencies did provide more funding for infrastructure and the instrumentation that you need to perform research through block grants. In the 1960s, the NSF and the Department of Defense were kicking up major programs to establish new data collection efforts — observatories, radio astronomy, or the Deep Sea Drilling project the NSF ran, collecting core samples from the ocean floor around the world. The Defense Advanced Research Projects Agency (DARPA) — back then the Advanced Research Projects Agency (ARPA) — was investing in nuclear test detection to monitor adherence to nuclear test ban treaties. Some of these were satellite observation methods for atmospheric testing. Some were seismic measurement methods for underground testing. ARPA supported the installation of a network of seismic monitors around the world. Those monitors are responsible for validating tectonic plate theory. Over the next decade, their readings mapped the tectonic plates of the earth. That large-scale investment in research infrastructure is not as common in the US research policy enterprise today.That's fascinating. I learned last year how modern that validation of tectonic plate theory was. Until well into my grandparents' lifetime, we didn't know if tectonic plates existed.Dan: Santi, when were you born?1997.Dan: So I'm a good decade older than you — I was born in 1985. When we were learning tectonic plate theory in the 1990s, it seemed like something everybody had always known. It turns out that it had only been known for maybe 25 years.So there's this idea of federal funding for science as these massive pieces of infrastructure, like the Hubble Telescope. But although projects like that do happen, the median dollar the Feds spend on science today is for an individual grant, not installing seismic monitors all over the globe.Dan: You applied for a grant to fund a specific project, whose contours you've outlined in advance, and we provided the funding to execute that project.Pierre: You want to do some observations at the observatory in Chile, and you are going to need to buy a plane ticket — not first class, not business class, very much economy.Let's move to current events. In February of this year, the NIH announced it was capping indirect cost reimbursement at 15% on all grants.What's the administration's argument here?Pierre: The argument is there are cases where foundations only charge 15% overhead rate on grants — and universities acquiesce to such low rates — and the federal government is entitled to some sort of “most-favored nation” clause where no one pays less in overhead than they pay. That's the argument in this half-a-page notice. It's not much more elaborate than that.The idea is, the Gates Foundation says, “We will give you a grant to do health research and we're only going to pay 15% indirect costs.” Some universities say, “Thank you. We'll do that.” So clearly the universities don't need the extra indirect cost reimbursement?Pierre: I think so.Dan: Whether you can extrapolate from that to federal research funding is a different question, let alone if federal research was funding less research and including even less overhead. Would foundations make up some of the difference, or even continue funding as much research, if the resources provided by the federal government were lower? Those are open questions. Foundations complement federal funding, as opposed to substitute for it, and may be less interested in funding research if it's less productive.What are some reasons that argument might be misguided?Pierre: First, universities don't always say, “Yes” [to a researcher wishing to accept a grant]. At MIT, getting a grant means getting special authorization from the provost. That special authorization is not always forthcoming. The provost has a special fund, presumably funded out of the endowment, that under certain conditions they will dip into to make up for the missing overhead.So you've got some research that, for whatever reason, the federal government won't fund, and the Gates Foundation is only willing to fund it at this low rate, and the university has budgeted a little bit extra for those grants that it still wants.Pierre: That's my understanding. I know that if you're going to get a grant, you're going to have to sit in many meetings and cajole any number of administrators, and you don't always get your way.Second, it's not an apples-to-apples comparison [between federal and foundation grants] because there are ways to budget an item as a direct cost in a foundation grant that the government would consider an indirect cost. So you might budget some fractional access to a facility…Like the mouse microscope I have to use?Pierre: Yes, or some sort of Cryo-EM machine. You end up getting more overhead through the back door.The more fundamental way in which that approach is misguided is that the government wants its infrastructure — that it has contributed to through [past] indirect costs — to be leveraged by other funders. It's already there, it's been paid for, it's sitting idle, and we can get more bang for our buck if we get those additional funders to piggyback on that investment.Dan: That [other funders] might not be interested in funding otherwise.Why wouldn't they be interested in funding it otherwise? What shouldn't the federal government say, “We're going to pay less. If it's important research, somebody else will pay for it.”Dan: We're talking about an economies-of-scale problem. These are fixed costs. The more they're utilized, the more the costs get spread over individual research projects.For the past several decades, the federal government has funded an order of magnitude more university research than private firms or foundations. If you look at NSF survey data, 55% of university R&D is federally funded; 6% is funded by foundations. That is an order of magnitude difference. The federal government has the scale to support and extract value for whatever its goals are for American science.We haven't even started to get into the administrative costs of research. That is part of the public and political discomfort with indirect-cost recovery. The idea that this is money that's going to fund university bloat.I should lay my cards on the table here for readers. There are a ton of problems with the American scientific enterprise as it currently exists. But when you look at studies from a wide range of folks, it's obvious that R&D in American universities is hugely valuable. Federal R&D dollars more than pay for themselves. I want to leave room for all critiques of the scientific ecosystem, of the universities, of individual research ideas. But at this 30,000-foot level, federal R&D dollars are well spent.Dan: The evidence may suggest that, but that's not where the political and public dialogue around science policy is. Again, I'm going to bring in a long arc here. In the 1950s and 1960s, it was, “We're in a race with the Soviet Union. If we want to win this race, we're going to have to take some risky bets.” And the US did. It was more flexible with its investments in university and industrial science, especially related to defense aims. But over time, with the waning of these political pressures and with new budgetary pressures, the tenor shifted from, “Let's take chances” to “Let's make science and other parts of government more accountable.” The undercurrent of Indirect Cost Recovery policy debates has more of this accountability framing.This comes up in this comparison to foundation rates: “Is the government overpaying?” Clearly universities are willing to accept less from foundations. It comes up in this perception that ICR is funding administrative growth that may not be productive or socially efficient. Accountability seems to be a priority in the current day.Where are we right now [August 2025] on that 15% cap on indirect costs?Dan: Recent changes first kicked off on February 7th, when NIH posted its supplemental guidance, that introduced a policy that the direct cost rates that it paid on its grants would be 15% to institutions of higher education. That policy was then adopted by the NSF, the DOD, and the Department of Energy. All of these have gotten held up in court by litigation from universities. Things are stuck in legal limbo. Congress has presented its point of view that, “At least for now, I'd like to keep things as they are.” But this has been an object of controversy long before the current administration even took office in January. I don't think it's going away.Pierre: If I had to guess, the proposal as it first took shape is not what is going to end up being adopted. But the idea that overhead rates are an object of controversy — are too high, and need to be reformed — is going to stay relevant.Dan: Partly that's because it's a complicated issue. Partly there's not a real benchmark of what an appropriate Indirect Cost Recovery policy should be. Any way you try to fund the cost of research, you're going to run into trade-offs. Those are complicated.ICR does draw criticism. People think it's bloated or lacks transparency. We would agree some of these critiques are well-founded. Yet it's also important to remember that ICR pays for facilities and administration. It doesn't just fund administrative costs, which is what people usually associate it with. The share of ICR that goes to administrative costs is legally capped at 26% of direct costs. That cap has been in place since 1991. Many universities have been at that cap for many years — you can see this in public records. So the idea that indirect costs are going up over time, and that that's because of bloat at US universities, has to be incorrect, because the administrative rate has been capped for three decades.Many of those costs are incurred in service of complying with regulations that govern research, including the cost of administering ICR to begin with. Compiling great proposals every two to four years and a new round of negotiations — all of that takes resources. Those are among the things that indirect cost funding reimburses.Even then, universities appear to under-recover their true indirect costs of federally-sponsored research. We have examples from specific universities which have reported detailed numbers. That under-recovery means less incentive to invest in infrastructure, less capacity for innovation, fewer clinical trials. So there's a case to be made that indirect cost funding is too low.Pierre: The bottom line is we don't know if there is under- or over-recovery of indirect costs. There's an incentive for university administrators to claim there's under-recovery. So I take that with a huge grain of salt.Dan: It's ambiguous what a best policy would look like, but this is all to say that, first, public understanding of this complex issue is sometimes a bit murky. Second, a path forward has to embrace the trade-offs that any particular approach to ICR presents.From reading your paper, I got a much better sense that a ton of the administrative bloat of the modern university is responding to federal regulations on research. The average researcher reports spending almost half of their time on paperwork. Some of that is a consequence of the research or grant process; some is regulatory compliance.The other thing, which I want to hear more on, is that research tools seem to be becoming more expensive and complex. So the microscope I'm using today is an order of magnitude more expensive than the microscope I was using in 1950. And you've got to recoup those costs somehow.Pierre: Everything costs more than it used to. Research is subject to Baumol's cost disease. There are areas where there's been productivity gains — software has had an impact.The stakes are high because, if we get this wrong, we're telling researchers that they should bias the type of research they're going to pursue and training that they're going to undergo, with an eye to what is cheaper. If we reduce the overhead rate, we should expect research that has less fixed cost and more variable costs to gain in favor — and research that is more scale-intensive to lose favor. There's no reason for a benevolent social planner to find that a good development. The government should be neutral with respect to the cost structure of research activities. We don't know in advance what's going to be more productive.Wouldn't a critic respond, “We're going to fund a little bit of indirect costs, but we're not going to subsidize stuff that takes huge amounts of overhead. If universities want to build that fancy new telescope because it's valuable, they'll do it.” Why is that wrong when it comes to science funding?Pierre: There's a grain of truth to it.Dan: With what resources though? Who's incentivized to invest in this infrastructure? There's not a paid market for science. Universities can generate some licensing fees from patents that result from science. But those are meager revenue streams, realistically. There are reasons to believe that commercial firms are under-incentivized to invest in basic scientific research. Prior to 1940, the scientific enterprise was dramatically smaller because there wasn't funding the way that there is today. The exigencies of war drew the federal government into funding research in order to win. Then it was productive enough that folks decided we should keep doing it. History and economic logic tells us that you're not going to see as much science — especially in these fixed-cost heavy endeavors — when those resources aren't provided by the public.Pierre: My one possible answer to the question is, “The endowment is going to pay for it.” MIT has an endowment, but many other universities do not. What does that mean for them? The administration also wants to tax the heck out of the endowment.This is a good opportunity to look at the empirical work you guys did in this great paper. As far as I can tell, this was one of the first real looks at what indirect costs rates look like in real life. What did you guys find?Dan: Two decades ago, Pierre and Bhaven began collecting information on universities' historical indirect cost rates. This is a resource that was quietly sitting on the shelf waiting for its day. That day came this past February. Bhaven and Pierre collected information on negotiated ICR rates for the past 60 years. During this project, we also collected the most recent versions of those agreements from university websites to bring the numbers up to the current day.We pulled together data for around 350 universities and other research institutions. Together, they account for around 85% of all NIH research funding over the last 20 years.We looked at their:* Negotiated indirect cost rates, from institutional indirect cost agreements with the government, and their;* Effective rates [how much they actually get when you look at grant payments], using NIH grant funding data.Negotiated cost rates have gone up. That has led to concerns that the overhead cost of research is going up — these claims that it's funding administrative bloat. But our most important finding is that there's a large gap between the sticker rates — the negotiated ICR rates that are visible to the public, and get floated on Twitter as examples of university exorbitance — and the rates that universities are paid in practice, at least on NIH grants; we think it's likely the case for NSF and other agency grants too.An institution's effective ICR funding rates are much, much lower than their negotiated rates and they haven't changed much for 40 years. If you look at NIH's annual budget, the share of grant funding that goes to indirect costs has been roughly constant at 27-28% for a long time. That implies an effective rate of around 40% over direct costs. Even though many institutions have negotiated rates of 50-70%, they usually receive 30-50%.The difference between those negotiated rates and the effective rates seems to be due to limits and exceptions built into NIH grant rules. Those rules exclude some grants, such as training grants, from full indirect cost funding. They also exclude some direct costs from the figure used to calculate ICR rates. The implication is that institutions receive ICR payments based on a smaller portion of their incurred direct costs than typically assumed. As the negotiated direct cost falls, you see a university being paid a higher indirect cost rate off a smaller — modified — direct cost base, to recover the same amount of overhead.Is it that the federal government is saying for more parts of the grant, “We're not going to reimburse that as an indirect cost.”?Dan: This is where we shift a little bit from assessment to speculation. What's excluded from total direct costs? One thing is researcher salaries above a certain level.What is that level? Can you give me a dollar amount?Dan: It's a $225,700 annual salary. There aren't enough people being paid that on these grants for that to explain the difference, especially when you consider that research salaries are being paid to postdocs and grad students.You're looking around the scientists in your institution and thinking, “That's not where the money is”?Dan: It's not, even if you consider Principal Investigators. If you consider postdocs and grad students, it certainly isn't.Dan: My best hunch is that research projects have become more capital-intensive, and only a certain level of expenditure on equipment can be included in the modified total direct cost base. I don't have smoking gun evidence, it's my intuition.In the paper, there's this fascinating chart where you show the institutions that would get hit hardest by a 15% cap tend to be those that do the most valuable medical research. Explain that on this framework. Is it that doing high-quality medical research is capital-intensive?Pierre: We look at all the private-sector patents that build on NIH research. The more a university stands to lose under the administration policy, the more it has contributed over the past 25 years — in research the private sector found relevant in terms of pharmaceutical patents.This is counterintuitive if your whole model of funding for science is, “Let's cut subsidies for the stuff the private sector doesn't care about — all this big equipment.” When you cut those subsidies, what suffers most is the stuff that the private sector likes.Pierre: To me it makes perfect sense. This is the stuff that the private sector would not be willing to invest in on its own. But that research, having come into being, is now a very valuable input into activities that profit-minded investors find interesting and worth taking a risk on.This is the argument for the government to fund basic research?Pierre: That argument has been made at the macro-level forever, but the bibliometric revolution of the past 15 years allows you to look at this at the nano-level. Recently I've been able to look at the history of Ozempic. The main patent cites zero publicly-funded research, but it cites a bunch of patents, including patents taken up by academics. Those cite the foundational research performed by Joel Habener and his team at Massachusetts General Hospital in the early 1980s that elucidated the role of GLP-1 as a potential target. This grant was first awarded to Habener in 1979, was renewed every four or five years, and finally died in 2008, when he moved on to other things. Those chains are complex, but we can now validate the macro picture at this more granular level.Dan: I do want to add one qualification which also suggests some directions for the future. There are things we still can't see — despite Pierre's zeal. Our projections of the consequence of a 15% rate cap are still pretty coarse. We don't know what research might not take place. We don't know what indirect cost categories are exposed, or how universities would reallocate. All those things are going to be difficult to project without a proper experiment.One thing that I would've loved to have more visibility into is, “What is the structure of indirect costs at universities across the country? What share of paid indirect costs are going to administrative expenses? What direct cost categories are being excluded?” We would need a more transparency into the system to know the answers.Does that information have to be proprietary? It's part of negotiations with the federal government about how much the taxpayer will pay for overhead on these grants. Which piece is so special that it can't be shared?Pierre: You are talking to the wrong people here because we're meta-scientists, so our answer is none of it should be private.Dan: But now you have to ask the university lawyers.What would the case from the universities be? “We can't tell the public what we spend subsidy on”?Pierre: My sense is that there are institutions of academia that strike most lay people as completely bizarre.Hard to explain without context?Pierre: People haven't thought about it. They will find it so bizarre that they will typically jump from the odd aspect to, “That must be corruption.” University administrators are hugely attuned to that. So the natural defensive approach is to shroud it in secrecy. This way we don't see how the sausage is made.Dan: Transparency can be a blessing and a curse. More information supports more considered decision-making. It also opens the door to misrepresentation by critics who have their own agendas. Pierre's right: there are some practices that to the public might look unusual — or might be familiar, but one might say, “How is that useful expense?” Even a simple thing like having an administrator who manages a faculty's calendar might seem excessive. Many people manage their own calendars. At the same time, when you think about how someone's time is best used, given their expertise, and heavy investment in specialized human capital, are emails, calendaring, and note-taking the right things for scientists [to be doing]? Scientists spend a large chunk of their time now administering grants. Does it make sense to outsource that and preserve the scientist's time for more science?When you put forward data that shows some share of federal research funding is going to fund administrative costs, at first glance it might look wasteful, yet it might still be productive. But I would be able to make a more considered judgment on a path forward if I had access to more facts, including what indirect costs look like under the hood.One last question: in a world where you guys have the ear of the Senate, political leadership at the NIH, and maybe the universities, what would you be pushing for on indirect costs?Pierre: I've come to think that this indirect cost rate is a second-best institution: terrible and yet superior to many of the alternatives. My favorite alternative would be one where there would be a flat rate applied to direct costs. That would be the average effective rate currently observed — on the order of 40%.You're swapping out this complicated system to — in the end — reimburse universities the same 40%.Pierre: We know there are fixed costs. Those fixed costs need to be paid. We could have an elaborate bureaucratic apparatus to try to get it exactly right, but it's mission impossible. So why don't we give up on that and set a rate that's unlikely to lead to large errors in under- or over-recovery. I'm not particularly attached to 40%. But the 15% that was contemplated seems absurdly low.Dan: In the work we've done, we do lay out different approaches. The 15% rate wouldn't fully cut out the negotiation process: to receive that, you have to document your overhead costs and demonstrate that they reached that level. In any case, it's simplifying. It forces more cost-sharing and maybe more judicious investments by universities. But it's also so low that it's likely to make a significant amount of high-value, life-improving research economically unattractive.The current system is complicated and burdensome. It might encourage investment in less productive things, particularly because universities can get it paid back through future ICR. At the same time, it provides pretty good incentives to take on expensive, high-value research on behalf of the public.I would land on one of two alternatives. One of those is close to what Pierre said, with fixed rates, but varied by institution types: one for universities, one for medical schools, one for independent research institutions — because we do see some variation in their cost structures. We might set those rates around their historical average effective rates, since those haven't changed for quite a long time. If you set different rates for different categories of institution, the more finely you slice the pie, the closer you end up to the current system. So that's why I said maybe, at a very high level, four categories.The other I could imagine is to shift more of these costs “above the line” — to adapt the system to enable more of these indirect costs to be budgeted as direct costs in grants. This isn't always easy, but presumably some things we currently call indirect costs could be accounted for in a direct cost manner. Foundations do it a bit more than the federal government does, so that could be another path forward.There's no silver bullet. Our goal was to try to bring some understanding to this long-running policy debate over how to fund the indirect cost of research and what appropriate rates should be. It's been a recurring question for several decades and now is in the hot seat again. Hopefully through this work, we've been able to help push that dialogue along. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.statecraft.pub

Scary skinny is back, and the ultra skinny look is hitting women and girls harder than ever. This episode takes a real look at why rapid, dramatic weight loss is being celebrated again, how celebrity culture and GLP1 drugs are fueling it, and what is really happening behind the filters. From hair loss and hormone crashes to influencer hypocrisy and hidden health fallout, this is an honest conversation about the new wellness lie. Listeners will walk away with clarity, context, and practical ways to protect themselves and their daughters from the pressure to keep getting smaller.  

Episode 2731 - Vinnie Tortorich and Chris Shaffer discuss the evolution of beliefs, what we tell ourselves, junk food trends, and more. https://vinnietortorich.com/2025/12/what-we-tell-ourselves-episode-2731 PLEASE SUPPORT OUR SPONSORS Pure Vitamin Club Pure Coffee Club NSNG® Foods VILLA CAPPELLI EAT HAPPY KITCHEN YOU CAN WATCH THIS EPISODE ON YOUTUBE - @FitnessConfidential Podcast What We Tell Ourselves Note: There is a discussion around Santa and beliefs—if you have little ones around while listening, we encourage listener discretion. The origin of the "Daisy Dukes" and the show Dukes of Hazard. (3:00) They discuss how information about topics like climate change has changed, and that we are always learning. Vinnie relates the belief in Santa to the belief in what is possible. (13:00) We tell ourselves things we want to be true, so we can get what we want. (16:30) Oral semiglutide's effects are supposed to be as effective as the injection, but there are still side effects. (21:00) "The Decaf study." They discuss decaf and caffeinated coffee and whether it is harmful enough. Taco Bell has its own soda flavor, Baja Blast. (28:00) They just launched their own pie based on the same flavor. People think they can get away with one thing if they believe they are compensating elsewhere, but that doesn't always work that way. CICO, or taking a GLP-1, is an example of this; people will indulge, thinking that the running or the GLP-1 will take care of the fallout. (36:00) The FDA is lifting black box warnings from women's estrodiol packaging. (51:00) This allows women options that they didn't think were possible before to treat perimenopause and menopausal symptoms. Our Sponsor Jaspr Air Scrubbers has a discount code, VINNIE, that gets you $400 off through Black Friday. Jaspr offers a lifetime warranty. Go to Jaspr.co for more information or to purchase. Don't forget to sign up for the NSNG VIP group. Vinnie's video workouts will be free to all members! (1:05:00) You can get on the wait list -https://vinnietortorich.com/vip/ Also, you'll want to join as soon as it opens, because once it closes again, it will be closed indefinitely. You can book a consultation with Vinnie to get guidance on your goals. https://vinnietortorich.com/phone-consultation-2/ More News Serena has added some of her clothing suggestions and beauty product suggestions to Vinnie's Amazon Recommended Products link. Self Care, Beauty, and Grooming Products that Actually Work! Don't forget to check out Serena Scott Thomas on Days of Our Lives on the Peacock channel. "Dirty Keto" is available on Amazon! You can purchase or rent it here.https://amzn.to/4d9agj1 Please make sure to watch, rate, and review it! Eat Happy Italian, Anna's next cookbook, is available! You can go to https://eathappyitalian.com You can order it from Vinnie's Book Club. https://amzn.to/3ucIXm Anna's recipes are in her cookbooks, website, and Substack — they will spice up your day! https://annavocino.substack.com/ Don't forget you can invest in Anna's Eat Happy Kitchen through StartEngine. Details are at Eat Happy Kitchen. https://eathappykitchen.com/ PURCHASE DIRTY KETO (2024) The documentary launched in August 2024! Order it TODAY! This is Vinnie's fourth documentary in just over five years. Visit my new Documentaries HQ to find my films everywhere: https://vinnietortorich.com/documentaries Then, please share my fact-based, health-focused documentary series with your friends and family. Additionally, the more views it receives, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! PURCHASE BEYOND IMPOSSIBLE (2022) Visit my new Documentaries HQ to find my films everywhere: https://vinnietortorich.com/documentaries REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere: https://vinnietortorich.com/documentaries FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere: https://vinnietortorich.com/documentaries

I am thrilled to reconnect with Nick Norwitz today. Nick is a researcher and educator with a mission to make metabolic health a mainstream concern. He graduated valedictorian from Dartmouth College, completed his PhD in metabolism at the University of Oxford, and earned his MD at Harvard Medical School. He has become known as a clinical researcher and metabolic health educator, speaking and writing on various topics, including brain health, microbiome, mitochondrial function, cholesterol, and more.  In our conversation, we discuss the challenges of providing evidence-based medicine, and Nick shares his personal story of overcoming inflammatory bowel disease with a ketogenic diet. We explore the research on statins reducing endogenous GLP-1 production, highlighting the importance of staying curious. We also clarify the different types of type 2 diabetes, the effects of biomolecular aging, and different perspectives on Lp(a).  Nick always provides thoughtful and valuable insights on a range of topics. His Substack is one of my favorites, sharing several ways to enhance your learning process, as a clinician or a layperson. IN THIS EPISODE, YOU WILL LEARN: How his struggle with inflammatory bowel disease led Nick to realize that the evidence-based care of western medicine is not always the best type of care, and how a ketogenic diet saved his life How a recent study highlighted several major physical issues statins cause, yet it went largely unnoticed in medicine and the media The need for clinicians to inform their patients about the potential side effects of their medications How physicians tend to ignore evidence in favor of one-sided messaging that erodes trust and undermines informed care The importance of remaining curious and acknowledging that what you learned initially might be incorrect How technological advances will make personalized medicine the future of healthcare The limitations of traditional one-size-fits-all randomized controlled trials The sub-phenotypes of type 2 diabetes How enzyme inhibitors (like statins) disrupt the gut microbiome How metabolic health and oxidative stress affect Lp(a), and how vitamin C can potentially reduce its impact Bio: Nick Norwitz Nick Norwitz, MD, PhD, is a researcher-educator whose mission is to “Make Metabolic Health Mainstream.” He graduated Valedictorian from Dartmouth College, majoring in Cell Biology and Biochemistry, before completing his PhD in Metabolism at the University of Oxford and his MD at Harvard Medical School.  Nick has made a name for himself as a clinical research and metabolic health educator, speaking and writing on topics ranging from brain health, the microbiome, and mental health to muscle physiology, mitochondrial function, and cholesterol and lipids. His mantra is “Stay Curious.” Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Nick Norwitz On YouTube, X, and Instagram His Substack

There is a widespread idea that bingeing has “protective” value for the binge eater—protection from difficult emotions, pain, stress, and other problems. I remember believing this when I was bulimic, and I know how convincing it can feel. In this episode, I talk about why the protection narrative may be holding you back in recovery, and how you can learn to see that bingeing isn't safety—it's dangerous and it's hurting you. You can learn to recognize and dismiss the protection thoughts and realize you're much safer without binge eating. Subscribe to my email list (and get my free Inspiration Booklet!) Episodes mentioned in this show: Episode 183: GLP-1 Medications, Food Noise, and Binge Eating Recovery with Marcus Kain Ep. 131: Ozempic and Eating Disorders with Robyn Goldberg RDN, CEDS-C Brain over Binge resources: Subscribe to the Brain over Binge Course for only $18.99 per month Get personalized support with one-on-one coaching or group coaching Get the Second Edition of Brain over Binge on Amazon and Audible, BarnesandNoble.com, Apple iBooks, or Kobo. Get the Brain over Binge Recovery Guide   Disclaimer: *The Brain over Binge Podcast is produced and recorded by Brain over Binge Recovery Coaching, LLC. All work is copyrighted by Brain over Binge Recovery Coaching, LLC, and all rights are reserved. As a disclaimer, the hosts of the Brain over Binge Podcast are not professional counselors or licensed healthcare providers, and this podcast is not a substitute for medical advice or any form of professional therapy. Eating disorders can have serious health consequences and you are strongly advised to seek medical attention for matters relating to your health. Please get help when you need it, and good luck on your journey.

Ozempic and other GLP-1 medications have become so normalized in Hollywood that it seems like every celebrity is on the jab. But actress and comedian Amy Schumer's headline-making transformation has sparked a whole new round of drama, and this time, it's hitting close to home. Divorce rumors are on the rise, and it seems like her alleged soon-to-be-ex-husband was a chubby chaser.  Kennedy Now Available on YouTube: ⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@KennedySavestheWorld⁠ Follow on TikTok: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@kennedy_foxnews⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Join Kennedy for Happy Hour on Fridays! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/playlist?list=PLWlNiiSXX4BNUbXM5X8KkYbDepFgUIVZj⁠⁠⁠ Learn more about your ad choices. Visit podcastchoices.com/adchoices

”You can have all the self-love in the world, and that does not protect you from systemic harm.”Body positivity is everywhere online, but is it really helping us heal? In this episode, Chrissy King joins me to explore why the mainstream body positivity message often leaves people feeling excluded or even more frustrated. We dig into shifting perspectives, the limits of focusing on individual confidence, and the systemic forces that shape our experiences in our bodies. Chrissy brings her lived experience and expertise to show why true body healing requires looking beyond “just love your body” and embracing a more inclusive, collective path.✅ What You'll Learn:How the body positivity movement began, how it's been co-opted, and why it often falls shortWhy mainstream body positivity focuses too much on individual confidence and not enough on systemic challengesThe importance of thinking collectively: healing goes beyond just ourselves and requires considering how everyone gets to exist in the worldWays intersectionality shapes our experience, and why focusing only on individual body image is incompleteHow diet culture and fatphobia are rooted in racism and white supremacy, and why dismantling these systems of oppression benefits all of usChrissy's take on Serena Williams' partnership with a GLP-1 companyWhy ongoing unlearning, compassion, and slow growth are essential to real body liberation work

Winner of the CTP Cup for IBIT Announcing the participants for the CTP Cup 2025 Calling a Code Red! Sam Altman’s declaration PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Interactive Brokers  Warm-Up - Winner of the CTP for IBIT - Announcing the participants for the CTP Cup 2025 - Calling a Code Red! Sam Altman's panic - Here come the Tariff lawsuits - - Smart Toilets are a thing (And learning the Bristol Scale) Markets - Horses can smell the barn.... Seasonal Trends - PR Teams - full throttle - (This is their Social Media) - Tax planning over the next couple of weeks may see some selling into year end Impressive Results - India's economy grew at a faster-than-expected pace of 8.2% in the quarter ended September against a forecast of 7.3% in a Reuters poll and 7.8% expansion in the previous quarter, data released last Friday showed. - The Indian government has cut consumer taxes on hundreds of items and implemented long-delayed labour reforms in the last three months as it tries to keep the domestic economy strong in the face of global uncertainties. - Strongest in 6 quarters - Economists said stockpiling for the festive season as well as expedited exports ahead of the 50% tariff deadline on August 27 might have contributed to the quarterly growth figures. - Manufacturing output rose 9.1% in the quarter ending in September from a year earlier against growth of 7.7% a quarter ago, while construction expanded 7.2% year-on-year from 7.6% a quarter ago. NVDA Spreading Out - Nvidia on Monday announced it has purchased $2 billion of Synopsys common stock as part of a strategic partnership to accelerate computing and artificial intelligence engineering solutions. - As part of the multiyear partnership, Nvidia will help Synopsys accelerate its portfolio of compute-intensive applications, advance agentic AI engineering, expand cloud access and develop joint go-to-market initiatives, according to a release. - Nvidia said it purchased Synopsys' stock at $414.79 per share (Now at $445) Amazon Ultra Fast Service - The parent company of Instacart fell nearly 4% after Amazon said it's testing “ultra-fast” delivery of groceries in Seattle and Philadelphia. - These deliveries take about 30 minutes or less, said Amazon. - Doordash and other delivery companies stocks also fell. Microstrategy - Strategy - Stock has been under pressure - Who knows what the company actully does anymore - Leverage Bitcoin play - issuing massive debt and convertibles to but Bitcoin - Stock down 39% this year and 52% 1 -year (Up 400% in the last 5 years) -Bitcoin dropped below $87k this week before staging a recovery bounce. Devil's Metal - Silver has outpaced gold in 2025, with a growth of about 71%, compared to gold's 54%. - Silver mine production has been decreasing for the past ten years, especially in Central and South America, due to mine closures, resource depletion and infrastructure challenges. - While industrial demand for silver is expected to decline slightly in 2025, the metal is increasingly used in electric vehicles, for AI components and in photovoltaics. - Some people are saying that people were having to transport silver by plane rather than on cargo ships to meet delivery demand INTERACTIVE BROKERS Check this out and find out more at: http://www.interactivebrokers.com/ Some Trump Updates: - Reiterates his view that Chair Powell should reduce rates. - Says he's negotiating with Democrats on healthcare. - Plans to give refunds out of collected tariffs. Crying Game - SoftBank Group founder Masayoshi Son on Monday downplayed the decision to offload the conglomerate's entire Nvidia stake, saying he “was crying” over parting with the shares. - Speaking at a forum in Tokyo Monday, Son addressed SoftBank's November disclosure that the firm had sold its holding in the American chip darling for $5.83 billion. - According to Son, SoftBank wouldn't have made the move if it didn't need to bankroll its next artificial intelligence investments, including a big bet on OpenAI and data center projects. Are Stocks Overvalued? CAPE RATIO Consumers... Consumer Confidence CODE RED -  Chief executive Sam Altman reportedly declared a “code red” on Monday, urging staff to improve its flagship product ChatGPT, an indicator that the startup's once-unassailable lead is eroding as competitors like Google and Anthropic close in. - In the memo, reported by the Wall Street Journal and The Information, Altman said the company will be delaying initiatives like ads, shopping and health agents, and a personal assistant, Pulse, to focus on improving ChatGPT. This includes core features like greater speed and reliability, better personalization, and the ability to answer more questions, he said. - Herein lies the problem with this entire tech market - what if ChatGPT fades to the sideline with $1.5Trillion promised over the next 5-7 years? - Remember, Google declared a Code Red after the arrival of ChatGPT. AI Takeover - Massachusetts Institute of Technology on Wednesday released a study that found that artificial intelligence can already replace 11.7% of the U.S. labor market, or as much as $1.2 trillion in wages across finance, health care and professional services. - The study was conducted using a labor simulation tool called the Iceberg Index, which was created by MIT and Oak Ridge National Laboratory. - The index simulates how 151 million U.S. workers interact across the country and how they are affected by AI and corresponding policy. Costco Sues - Costco filed a lawsuit asking for a full refund of tariffs the warehouse club giant has paid since President Donald Trump imposed “reciprocal” and “fentanyl” tariffs earlier this year. - Costco sued the Trump administration to get a full refund of new tariffs it paid so far this year, and to block those import duties from continuing to be collected from the retail warehouse club giant as a Supreme Court case plays out. - Costco is worried that it would lose the money even if the Tariffs were deemed illegal. Fat Cutting -  Eli Lilly said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect. - Starting Dec. 1, cash-paying patients with a valid prescription can pay $299 to $449 per month for Zepbound vials on LillyDirect, depending on the dose, down from a previous range of $349 to $499 per month. - The announcement comes just weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access and afford. Smart Toilets - This year industry giants Toto Ltd. and Kohler Co. introduced smart toilets capable of analyzing what is in the bowl - Launched in August, the latest model in the Neorest line starts at roughly $3,200. - It uses an LED light and a sensor to read the shape, color, hardness and volume of stool as it drops, and sends data to a smartphone app in less than a minute. - Each toilet can support as many as six users — enough for most households — while some companies have bought multiple units for their employees. Toto aims to sell 7,300 units annually by 2028. - For now the stool-scanning Neorest is available only in Japan. - The app analyzes bowel movements against the Bristol scale, which is commonly used to diagnose constipation, inflammation or diarrhea, and offers simple recommendations such as eating more fiber and drinking more water, or even menu suggestions, like vegetable soup. Bristol Scale Feel Good - Entrepreneur Michael Dell and his wife, Susan, will deposit $250 in the individual investment accounts of 25 million American children in a $6.25 billion philanthropic pledge as part of the Trump administration's Invest America initiative. - $250 each child born after between 2015 and 2025 - The money will go to the accounts of children who live in ZIP codes where the median family's income is $150,000 or less, according to a spokesperson for the Dells. Love the Show? Then how about a Donation? Announcing the Winner for iShares Bitcoin Trust ETF (IBIT) Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! CTP CUP 2025 Here is the list of players: Jim Beaver Mike Kazmierczak Joe Metzger Ken Degel David Martin Dean Wormell Neil Larion Mary Lou Schwarzer Eric Harvey (2024 Winner) FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Full shownotes, transcript and resources here: https://soundbitesrd.com/300                    This episode is sponsored. Commercial support has been provided by Danone North America & OIKOS. Dr. Gitanjali Srivastava is a paid consultant to Danone North America. No brands are discussed or promoted.  This episode explores strategies for maintaining weight loss and overall wellness following the use of GLP-1 medications. Listeners will learn how behavioral, nutritional and clinical approaches can help patients sustain progress and build long-term healthy habits with shifts to their dosage or after discontinuing treatment. Tune in to this episode to learn about: ·       the STEP and SURMOUNT 4 trial findings ·       the chronic pathological state of obesity ·       how GLP-1 meds curb food noise and disordered eating ·       how GLP-1 meds are intended to be used for weight loss ·       the crucial role of behavior change ·       statistics about how and why people plan to stay on or go off the meds ·       key behavior changes that GLP-1 users can adopt to maximize their success ·       the importance of structured exercise ·       how "clock genes" play a role in metabolic function ·       the power of fiber, protein and fluids in dietary habits ·       the three pillars: protein, portions and patterns ·       various reasons that people stop taking GLP-1s ·       what happens when people stop taking GLP-1s ·       stigma and bias with weight loss medications ·       the many challenges in maintaining weight loss ·       how dietitians are an essential part of the care team ·       the importance of communicating with patients about side effects ·       how to support patients who are pausing, cycling or microdosing their GLP-1s ·       resources for health professionals and the public  This episode (GLP-1 Meds and Then What? Turning Weight Loss into Lifelong Wellness) awards 1.0 CPEUs in accordance with the Commission on Dietetic Registration's CPEU Prior Approval Program. Visit https://soundbitesrd.com/300 to access the CPEU activity.

I'm excited to have Povilas Sabaliauskas, the CEO of Pulsetto, joining me for a two-part series. I truly believe that the Pulsetto is the best vagus nerve stimulator on the market. Today, in Part 1, Povilas explains what the vagus nerve is and how it acts as a necessary mental toothbrush for us. The Benefits of Vagus Nerve Stimulation Helps the body shift from fight-or-flight to relaxation Enhances sleep quality and supports faster recovery Builds long-term stress resilience  Calms the nervous system and promotes mental well-being  Bio: Povilas Sabaliauskas Povilas Sabaliauskas is the co-founder and CEO of Pulsetto, one of the fastest-growing wellness tech companies in the world.  A leader in non-invasive neuromodulation, Pulsetto is redefining how we approach stress, sleep, and recovery — through wearable vagus nerve stimulation backed by science and loved by high-performers around the globe.  With a background in tech and performance coaching, Povilas has become a passionate advocate for making cutting-edge wellness tools accessible to everyone — not just elite athletes or clinical patients.  Under his leadership, Pulsetto has partnered with leading researchers, completed clinical trials, and grown to over 100,000 users across Europe and the U.S. Povilas brings a unique mix of business strategy, biohacking curiosity, and real-world stress recovery insights — making him a fresh voice in the growing world of neuromodulation and mental resilience. In this episode: Why the vagus nerve is called the highway to health  How the vagus nerve controls the body's ability to switch between stress and relaxation How electrical stimulation can help the body to switch from fight-or-flight to rest-and-digest  How vagus nerve stimulation boosts stress resilience, sleep quality, and recovery How daily practices can train your body to handle stress more effectively How the Pulsetto device acts like a mental toothbrush to reset the brain Links and Resources: Try Halo (Salt) Therapy for respiratory and skin health. Call 319-363-0033 to schedule your session. ⁠⁠⁠Use Code FIBER to get 10% off GLP-1 Fiber Guest Social Media Links: Povilas Sabaliauskas on LinkedIn Pulsetto Device on YouTube  YouTube: Immediate Relief from Stress & Burnout with Pulsetto and CEO Povilas Sabaliauskas YouTube: Interview with Nick Engerer from A Longer Life and Povilas Sabaliauskas from Pulsetto  YouTube: How to Reduce Stress and Calm Your Nervous System in Just 4 Minutes using a New Device Relative Links for This Show: Use the code Dr. Stephanie Gray for 10% off Follow Your Longevity Blueprint  On Instagram| Facebook| Twitter| YouTube | LinkedIn Get your copy of the Your Longevity Blueprint book and claim your bonuses here Find Dr. Stephanie Gray and Your Longevity Blueprint online   Follow Dr. Stephanie Gray  On Facebook| Instagram| Youtube | Twitter | LinkedIn Integrative Health and Hormone Clinic Podcast production by Team Podcast 

In this bonus episode, Dani sits down with Dr. Shannon Ritchey, Doctor of Physical Therapy and founder of Evlo, for one of the most helpful, myth-busting conversations we've ever had about fitness, strength training, pregnancy, and women's health. Shannon breaks down why so many of us feel confused about exercise, what actually matters when you're short on time, and why “gentle consistency” might be the secret to finally seeing results without burning out. She shares her own story of overtraining, chronic pain, and rebuilding her approach from the ground up and why so many women are unknowingly doing too much instead of training with intention. They go deep on postpartum fitness, strength training during pregnancy, weighted vests, Pilates vs. lifting, GLP-1 medications, body recomposition, protein, recovery, and what women really need to know if they want to build muscle and feel stronger at every stage of life. If you've ever wondered where to start, whether you're “doing it right,” or how to make fitness fit your actual life, this conversation will make everything finally click Visit evlofitness.com and use code DANI for 6 weeks free. You get a free two week trial, plus your first month at $0 Make sure you're subscribed to our official channel on YouTube, @deinfluencedpodcast, and follow us on Spotify, Apple Podcasts, or wherever you get your De-Influenced fix! Stay connected with us on Instagram and TikTok @deinfluencedpodcast, and as always thank you for being a part of this journey. Produced by Dear Media